



10-17-05

15/1633 \$

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	09/757,555
		Filing Date	January 9, 2001
		First Named Inventor	Levon M. KHACHIGIAN
		Art Unit	1633
		Examiner Name	J. Epps-Ford
Total Number of Pages in This Submission	10 + 28 Refs.	Attorney Docket Number	529282000220

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form (1 page in duplicate) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (3 pages) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08a/b (2 pages in duplicate) 2. References (28) 3. Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	MORRISON & FOERSTER LLP (Customer No. 25226)		
Signature			
Printed name	Shantanu Basu		
Date	October 14, 2005	Reg. No.	43,318

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV544978607US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: October 14, 2005

Signature:

(Georgina Matos)



PTO/SB/17 (12-04v2)

Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL For FY 2005		Complete if Known	
		Application Number	09/757,555
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date	January 9, 2001
		First Named Inventor	Levon M. KHACHIGIAN
		Examiner Name	J. Epps-Ford
TOTAL AMOUNT OF PAYMENT		(\$)	180.00
		Attorney Docket No.	529282000220

METHOD OF PAYMENT (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: 03-1952
Deposit Account Name: Morrison & Foerster LLP	
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
Application Type	Filing Fees	Small Entity	Search Fees	Small Entity	Examination Fees	Small Entity	Fees Paid (\$)
	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
Fee Description						Small Entity	
						Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
6		- 20 = 0	x 50.00 =	0.00	Fee (\$)		Fee Paid (\$)
					360.00		0.00
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
1		- 3 = 0	x 200.00 =	0.00			
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets		Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)	
- 100 =		/50	(round up to a whole number) x		=		
4. OTHER FEE(S)							
Non-English Specification, \$130 fee (no small entity discount)						Fees Paid (\$)	
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement						180.00	

SUBMITTED BY			
Signature	<i>Shantanu Basu</i>	Registration No. (Attorney/Agent)	43,318
Name (Print/Type)	Shantanu Basu	Telephone	(650) 813-5995
		Date	October 14, 2005

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV544978607US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: October 14, 2005


Signature:

Georgina Matos
(Georgina Matos)

Patent

Docket No. 529282000220

Client Reference No. 1311-7567



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Levon M. KHACHIGIAN

Serial No.: 09/757,555

Filing Date: January 9, 2001

For: INHIBITION OF PROLIFERATION OF
CELLS

Examiner: J. Epps-Ford

Group Art Unit: 1633

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

10/19/2005 HLE333 00000025 031952 09757555

01 FC:1806 180.00 DA

- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including

Application Serial No. 09/757,555

Patent
Docket No. 529282000220
Client Reference No. 1311-7567

extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 529282000220.

Dated: October 14, 2005

Respectfully submitted,

By 

Shantanu Basu

Registration No.: 43,318
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5995



Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/757,555
				Filing Date	January 9, 2001
				First Named Inventor	Levon M. KHACHIGIAN
				Art Unit	1633
				Examiner Name	J. Epps-Ford
Sheet	1	of	2	Attorney Docket Number	529282000220

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	1.	Adamis, A.P. et al. (1999). "Angiogenesis and Ophthalmic Disease," <i>Angiogenesis</i> 3:9-14.		
	2.	Bhushan, M. et al. (2002). "Topical Review: Recent Advances in Cutaneous Angiogenesis," <i>British Journal of Dermatology</i> 147:418-425.		
	3.	Dichtl, W. et al. (2003). "HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells," <i>Arterioscler. Thromb. Vasc. Biol.</i> 23:58-63.		
	4.	Fahmy, R.G. et al. (2004). "Locked Nucleic Acid Modified DNA Enzymes Targeting Early Growth Response-1 Inhibit Human Vascular Smooth Muscle Cell Growth," <i>Nucleic Acids Research</i> 32(7):2281-2285.		
	5.	Ferrara, N. et al. (June 2003). "The Biology of VEGF and Its Receptors," <i>Nature Medicine</i> 9(6):669-676.		
	6.	Hofer, G. et al. (November 8, 1996). "Transcription Factor Egr-1 Regulates Glomerular Mesangial Cell Proliferation," <i>The Journal of Biological Chemistry</i> 271(45):28306-28310.		
	7.	Ito, Y. et al. (October 15, 2003). "Inhibition of Angiogenesis and Vascular Leakiness by Angiopoietin-Related Protein 4," <i>Cancer Research</i> 63:6651-6657.		
	8.	Janssen, Y.M.W. et al. (1997). "Differential Induction of c-fos, c-jun, and Apoptosis in Lung Epithelial Cells Exposed to ROS or RNS," <i>Lung Cell. Mol. Physiol.</i> 17:L789-L796.		
	9.	Krzystolik, M.G. et al. (March 2002). "Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti-Vascular Endothelial Growth Factor Antibody Fragment," <i>Arch. Ophthalmol.</i> 120:338-346.		
	10.	Kukita, T. et al. (1997). "Regulation of Osteoclastogenesis by Antisense Oligodeoxynucleotides Specific to Zinc Finger Nuclear Transcription Factors Egr-1 and WT1 in Rat Bone Marrow Culture System," <i>Endocrinology</i> 138(10):4384-4389.		
	11.	Kurreck, J. et al. (March 1, 2002). "Comparative Study of DNA Enzymes and Ribozymes Against the Same Full-Length Messenger RNA of the Vanilloid Receptor Subtype 1," <i>The Journal of Biological Chemistry</i> 277(9):7099-7107.		
	12.	Leenders, W. et al. (April 2002). "Design of a Variant of Vascular Endothelial Growth Factor-A (VEGF-A) Antagonizing KDR/Flk-1 and Flt-1," <i>Laboratory Investigation</i> 82(4):473-481.		
	13.	Malde, R.E. et al. (1995). "Tumor-Promoting Activity of 2,4-Dinitrofluorobenzene," <i>Int. J. Cancer</i> 60:545-553.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa- 1015317

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/757,555
				Filing Date	January 9, 2001
				First Named Inventor	Levon M. KHACHIGIAN
				Art Unit	1633
				Examiner Name	J. Epps-Ford
				Attorney Docket Number	529282000220
Sheet	2	of	2		

14.	Mitchell, A. et al. (2004). "Inhibition of Human Breast Carcinoma Proliferation, Migration, Chemoinvasion and Solid Tumour Growth by DNAzymes Targeting the Zinc Finger Transcription Factor EGR-1," <i>Nucleic Acids Research</i> 32(10):3065-3069.
15.	Momiyama, N. et al. (August 1996). "Suppression of <i>c-jun</i> by Antisense Oligonucleotides Inhibits Cell Adhesion but not Respiratory Burst during Phorbol Ester-induced Differentiation of U937 Human Monoblastic Cells," <i>Cell Growth & Differentiation</i> 7:1005-1012.
16.	Nakamura, H. (2002). "Introduction of DNA Enzyme for Egr-1 Into Tubulointerstitial Fibroblasts by Electroporation Reduced Interstitial α -smooth Muscle Actin Expression and Fibrosis in Unilateral Ureteral Obstruction (UUO) Rats," <i>Gene Therapy</i> 9:495-502.
17.	Nguyen, H.Q. et al. (January 29, 1993). "The Zinc Finger Transcription Factor Egr-1 Is Essential for and Restricts Differentiation Along the Macrophage Lineage," <i>Cell</i> 72:197-209.
18.	Pan, W-H. et al. (2004). "Identification of Efficient Cleavage Sites in Long-Target RNAs" Chapter 9 <i>In Methods in Molecular Biology: Ribozymes and siRNA Protocols</i> , Second Edition, Sioud, M. ed., Humana Press, Inc.: Totowa, NJ, 252:125-144.
19.	Ross, R. (January 14, 1999). "Atherosclerosis - An Inflammatory Disease," <i>The New England Journal of Medicine</i> 340(2):115-126.
20.	Santoro, S.W. et al. (April 1997). "A General Purpose RNA-Cleaving DNA Enzyme," <i>Proc. Natl. Acad. Sci. USA</i> 94:4262-4266.
21.	Schärer, L.J. et al. (December 2003). "Approaches for the Sequence-Specific Knockdown of mRNA," <i>Nature Biotechnology</i> 21(12):1457-1465.
22.	Sells, S.F. et al. (February 1995). "The Zinc Finger Transcription Factor EGR-1 Impedes Interleukin-1-Inducible Tumor Growth Arrest," <i>Molecular and Cellular Biology</i> 15(2):682-692.
23.	Suggs, S.V. et al. (July 25, 1990). "cDNA Sequence of the Human Cellular Early Growth Response Gene Egr-1," <i>Nucleic Acids Research</i> 18(14):4283.
24.	van Nieuw Amerongen, G.P. et al. (2003). "Targets for Pharmacological Intervention of Endothelial Hyperpermeability and Barrier Function," <i>Vascular Pharmacology</i> 39:257-272.
25.	Wang, N. et al. (2001). "Adenovirus-Mediated Overexpression of Dominant-Negative Mutant of c-Jun Prevents Intercellular Adhesion Molecule-1 Induction by LDL," <i>Arterioscler. Thromb. Vasc. Biol.</i> 21:1414-1420.
26.	Yamada, M. et al. (2003). "Molecular Mechanism and Role of Endothelial Monocyte Chemoattractant Protein-1 Induction by Vascular Endothelial Growth Factor," <i>Arterioscler. Thromb. Vasc. Biol.</i> 23:1996-2001.
27.	Yokota, T. et al. (2004). "siRNA-Based Inhibition Specific for Mutant SOD1 with Single Nucleotide Alternation in Familial ALS, Compared with Ribozyme and DNA Enzyme," <i>Biochemical and Biophysical Research Communications</i> 314:283-291.
28.	Zhang, G. et al. (May 5, 2004). "Effect of Deoxyribozymes Targeting c-Jun on Solid Tumor Growth and Angiogenesis in Rodents," <i>Journal of the National Cancer Institute</i> 96(9):683-696.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

pa- 1015317